Novo Nordisk (NVO.N) raised its full-year guidance for the second time this year, citing higher sales expectations for its obesity and diabetes medicines. Adjusted operating profit for Q2 2026 was DKK 33.389bn. The company now expects maximum declines in sales and profit of 6% this year at constant currency, narrowed from a prior worst-case of a 12% decline. Novo Nordisk said it is competing with Eli Lilly (LLY.N) in the obesity market, which it expects could reach about $120bn a year by 2030.